Balance Sheet

Accounts Payables Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Sanofi (SNY) Notes Payables (2016 - 2018)

Sanofi's Notes Payables history spans 4 years, with the latest figure at $1.2 million for Q2 2018.

On a quarterly basis, Notes Payables changed N/A to $1.2 million in Q2 2018 year-over-year; TTM through Jun 2018 was $1.2 million, a N/A change, with the full-year FY2015 number at $20.0 million, changed N/A from a year prior.
Notes Payables hit $1.2 million in Q2 2018 for Sanofi, down from $12.4 million in the prior quarter.
Over the last five years, Notes Payables for SNY hit a ceiling of $19.7 million in Q4 2015 and a floor of $1.2 million in Q2 2018.
Historically, Notes Payables has averaged $11.1 million across 3 years, with a median of $12.4 million in 2016.